Compare ZVIA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | GOSS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.4M | 88.6M |
| IPO Year | 2021 | 2018 |
| Metric | ZVIA | GOSS |
|---|---|---|
| Price | $1.26 | $0.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $4.93 | $4.19 |
| AVG Volume (30 Days) | 335.8K | ★ 6.8M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $161,259,000.00 | $48,471,000.00 |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $6.87 | $201.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $1.11 | $0.32 |
| 52 Week High | $3.66 | $3.87 |
| Indicator | ZVIA | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 33.42 |
| Support Level | $1.12 | $0.33 |
| Resistance Level | $2.78 | $0.47 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 59.46 | 12.33 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).